Today’s Trending Healthcare/Biotech Stocks

The future of healthcare is changing right in front of our eyes, mainly through digital technologies. In medicine and healthcare, digital technology could aid in transforming flawed healthcare systems into sustainable ones by aligning the relationship between medical professionals and patients, while providing less expensive and more effective solutions for diseases.

The Frost & Sullivan Healthcare and Life Sciences experts are predicting large disruptions, transformations and innovations in the coming years as the healthcare industry continues to overhaul outmoded business models.

“Our interactive workshop is designed to help managers and CEOs understand key issues affecting the healthcare industry globally,” noted Sandeep Sinha, VP & Head, Healthcare and Life Sciences, Frost & Sullivan. “Advances in areas ranging from cancer immunotherapy products to blood testing, as well as the convergence of cutting-edge technology such as artificial intelligence and blockchain will help shape the healthcare industry into a much-anticipated, value-based care paradigm.”

With the aging population growing and demand for innovative medical technology rising, here are three healthcare stocks following the industry’s latest trend in focus this week.

Premier Health Group, Inc. (PHGRF) (PHGI) announced an update to its expansion plans into the Cannabis clinic space by a series of acquisitions, partnerships and/or launching a new Canada-based chain in the first half of 2019. Premier Health has engaged discussions with Licensed Producers under the Access to Cannabis for Medical Purposes Regulation (ACMPR), other licensed medical cannabis companies as well as government officials in order to establish a framework for both patient and physician education.

“Cannabis clinics fit in perfectly with our existing Telemedicine services and comprehensive app plans. The patient will not only be able to see their family doctor with our app, but also connect with their Cannabis clinic healthcare worker, the education nurse and eventually even the pharmacy or LP that is providing the prescription. This team based and encompassing approach will provide the best and most convenient care for our patients” said Dr. Essam Hamza, CEO.

The company has also announced its plans to enter the Pharmacy market via acquisition and/or launching a new Canada based pharmacy in H1–2019 and is actively reviewing a pipeline of additional pharmacy partners which include bricks and mortar locations for acquisition and strategic new retail opportunities for pharmacies.

Premier Health focuses on developing innovative approaches that combine human skill-based expertise with emerging technologies for the healthcare industry. The company entered the primary care clinic and healthcare technology business via the HealthVue transaction, obtaining access to a group of four Greater Vancouver-based fully integrated medical clinics with a 10-year history, 22 health care professionals and over 100,000 active patients.

Tonix Pharmaceuticals Holding Corp. (TNXP) announced that it has received the official minutes from the October 29th Breakthrough Therapy Type B Clinical Guidance meeting with the U.S. Food and Drug Administration (FDA). The minutes are consistent with the preliminary guidance that Tonix had received at the meeting, confirming the FDA’s acceptance of the new Phase 3 “RECOVERY” study design evaluating Tonmya.

Seth Lederman, M.D., President and CEO commented, “The minutes from our Breakthrough Therapy Clinical Guidance meeting with the FDA are consistent with our previous assessment. We are moving forward expeditiously to initiate the RECOVERY study in the first quarter of 2019 and expect to have topline data in the first half of 2020.”

Tonix is a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense through potential medical counter-measures. The company’s pipeline includes: Tonmya. TNX-102 SL targeting Alzheimer’s disease under a separate IND to support a Phase 2, TNX-601 (tianeptine oxalate) is in the pre-IND application stage for PTSD, and TNX-801, a potential smallpox-preventing vaccine in the pre-IND application stage.

Catalyst Pharmaceuticals (CPRX) announced that the FDA has approved Firdapse® (amifampridine) 10 mg tablets for the treatment of adults with Lambert-Eaton Myasthenic Syndrome (LEMS), which has already been approved in Europe. This is the first approval of a treatment for LEMS in the US and it is expected to be commercially available in Q1 2019.

“The FDA’s approval of Firdapse is a potentially transformative milestone in the lives of patients in the U.S. suffering with LEMS, as it now gives adult LEMS patients access to a new first-in-class-therapy,” said Patrick J. McEnany, Chairman and CEO “The approval of Firdapse is a crowning achievement for our company and an important step forward in our transition into a premier neurological rare disease company. We continue to prepare for what we hope will be a successful launch based on productive discussions with payers, our efforts in patient identification and our development of a field-based commercial infrastructure.

Catalyst is a biopharmaceutical company focused on developing and commercializing innovative therapies for rare, chronic neuromuscular and neurological diseases. Catalyst will host a conference call and webcast to discuss its commercialization plan for Firdapse, including the cost of therapy, on December 13, 2018 at 8:30 AM ET.



This Blog is an affiliate of Midam Ventures LLC. Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. MIDAM was hired for a period from 10/1/2018–4/1/2019 to publicly disseminate information about Premier Health Group Inc. Midam was paid $100,000 (CASH) & “500,000” shares of restricted common shares, they own zero shares that were purchased in the open market. Once the (6) six-month restriction is complete on 4/1/2018, Midam plans to sell the “500,000” shares of Premier Health Group Inc. that they hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. Midam may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click here for full Midam disclaimer.